| Literature DB >> 36079835 |
Syeda Tasmia Asma1, Otilia Bobiş2, Victoriţa Bonta2, Ulas Acaroz1, Syed Rizwan Ali Shah3, Fatih Ramazan Istanbullugil4, Damla Arslan-Acaroz5.
Abstract
Bee products have been extensively employed in traditional therapeutic practices to treat several diseases and microbial infections. Numerous bioactive components of bee products have exhibited several antibacterial, antifungal, antiviral, anticancer, antiprotozoal, hepatoprotective, and immunomodulatory properties. Apitherapy is a form of alternative medicine that uses the bioactive properties of bee products to prevent and/or treat different diseases. This review aims to provide an elaborated vision of the antiviral activities of bee products with recent advances in research. Since ancient times, bee products have been well known for their several medicinal properties. The antiviral and immunomodulatory effects of bee products and their bioactive components are emerging as a promising alternative therapy against several viral infections. Numerous studies have been performed, but many clinical trials should be conducted to evaluate the potential of apitherapy against pathogenic viruses. In that direction, here, we review and highlight the potential roles of bee products as apitherapeutics in combating numerous viral infections. Available studies validate the effectiveness of bee products in virus inhibition. With such significant antiviral potential, bee products and their bioactive components/extracts can be effectively employed as an alternative strategy to improve human health from individual to communal levels as well.Entities:
Keywords: antiviral properties; bee bread; bee pollen; bee venom; beeswax; bioactive substances; honey; nutrients; propolis; royal jelly
Mesh:
Substances:
Year: 2022 PMID: 36079835 PMCID: PMC9460612 DOI: 10.3390/nu14173579
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Antiviral properties of bee products.
Figure 2General composition of honey.
Figure 3Chemical structures of some important phenolic components in honey; (A) flavonoids and (B) phenolic acids.
Antiviral activities of honey and its components.
| Honey or Its Compounds | Organism | Tested Model | Outcome of the Study | References |
|---|---|---|---|---|
| Honey extract (Camelyn) | SARS-CoV-2 | In vitro (plaque reduction assay) baby hamster kidney cell line 21 (BHK-21), bone marrow-derived hematopoietic stem cells (HSCs), and splenic cells | Showed an inhibitory effect with an EC50 value from 85.7 μg/mL to 192.4 μg/mL. | [ |
| Honey | Rubella virus | In vitro African green monkey kidney cells | Inhibited the virus at all concentrations (1:1 to 1:1000 dilutions). | [ |
| Honey | HSV-1 | In vitro (plaque assay technique) Vero cells | Showed the highest inhibitory effect at 500 μg/mL and reduced viral load from 70795 to 43.3. | [ |
| Methylglyoxal | Influenza B virus | In vitro | Inhibited influenza B virus replication, with 50% inhibitory concentrations ranging from 23–140 μM. | [ |
| Kanuka honey | Herpes simplex labialis | Human model: 952 adults participated to compare the effect of Kanuka honey to 5% aciclovir cream | There was no difference in effectiveness compared with 5% acyclovir. | [ |
| Honey | Common cold | Human model (cohort study): 122 students participated | Especially after six weeks of honey application, common cold frequency was lower than in the control group. | [ |
| Tualang honey | HIV | Human model: 95 asymptomatic HIV-positive subjects participated | Ameliorated CD4 count, viral load, and quality of life. | [ |
| Iranian honeys (8 monofloral honey types obtained from | HIV-1 | In vitro peripheral blood mononuclear cells | Showed potent anti-HIV-1 activity in 6 of 8 monofloral honeys with EC50 values ranging from 5 to 105 µg/mL. | [ |
| Honey | HSV-1 | In vitro Vero cells | Showed complete inhibitory effect at 5% and higher concentrations. | [ |
| Honey (garlic and ginger decoction) | Influenza virus | In vitro human peripheral blood mononuclear cells | Decreased replication of the H1N2. | [ |
| Honeydew, manuka, and rewarewa honey | Adenovirus, rubella virus, and HSV | In vitro | Increased antiviral activity with the concentration of honey and time the virus was exposed to it. | [ |
Figure 4Honey and its components general mode of action against viruses.
Figure 5Main identified constituents of bee pollen and bee bread.
Protein content of bee pollen originating from different countries.
| Country | Origin | Protein Content (g/100 g) | References |
|---|---|---|---|
| Brazil | Heterofloral | 8.4–40.5 | [ |
|
| 23.0–24.5 | [ | |
|
| 11.7–33.9 | [ | |
|
| 17.6–21.2 | ||
| China |
| 20.7 | [ |
|
| 14.3 | ||
|
| 15.3 | ||
|
| 14.9 | ||
| Egypt |
| 29.0 | [ |
|
| 23.3 | ||
|
| 35.5 | ||
| Portugal | Heterofloral | 18.8–34.2 | [ |
|
| 23.0–27.1 | [ | |
| Serbia | Heterofloral | 14.8–27.2 | [ |
|
| 19.9 | ||
|
| 24.8 | ||
| Spain | Heterofloral | 12.5–20.8 | [ |
|
| 12.6–22.5 |
Figure 6General composition of propolis.
Antiviral activities of propolis and its components.
| Propolis Type and Its Components | Organism | Tested Model | Outcome of the Study | References |
|---|---|---|---|---|
| Mexican propolis | Canine distemper virus | In vitro African green monkey kidney cells | Propolis application decreased viral expression and correlated with increased cell viability. | [ |
| Propolis extracts | HSV-1 | In vitro RC-37 cells | IC50 values of aqueous and ethanol extracts were determined at 0.0004% and 0.000035%, respectively. | [ |
| Propolis | HIV-1 | In vitro | Propolis abolished syncytium formation at 4.5 micrograms/mL and decreased p24 antigen production by as much as 90–100%. | [ |
| Propolis extracts | HSV-1 and HSV-2 | In vitro | Standardized preparations of propolis exhibited antiviral bioactivity. | [ |
| Brazilian propolis (kaempferol, KF and p-coumaric acid, and p-CA) | Human rhinoviruses (HRVs) | In vitro HeLa cells | They inhibited HRV-3 infection when added during the early stages following virus inoculation. | [ |
| Propolis | HSV-1 | In vitro Vero cells in vivo newborn rats | The addition of 10% propolis extract led to 80–85% protection. | [ |
| Propolis extract GH-2002 | Varicella zoster virus | In vitro LEP cells | IC50 value was determined to be 64 μg/mL. | [ |
| Propolis extract ACF® | HSV-1 and HSV-2 | In vitro MDBK cells | Showed pronounced virucidal effect and interfered with virus adsorption. | [ |
Chemical components of bee venom.
| Bee Venom Components | Dry Weight% | |
|---|---|---|
| Peptides | Melittin | 40–50 |
| Apamine, MCD | 2–3 | |
| Secapine | 0.5–2 | |
| Minimine | 2 | |
| Pamine | 1–3 | |
| Adolapine | 0.5–1 | |
| Protease inhibitor | 0.1–0.8 | |
| Procamine (A, B), tertiapine, cardiopep, and melittin-F | 1–2 | |
| Proteins | Phospholipase A2 | 10–12 |
| Hyaluronidase | 1–2 | |
| Phosphatase and phospholipase B | 1 | |
| α-Glucosidase | 0–6 | |
| Sugars | Glucose and fructose | 2–4 |
| Minerals | Ca, Mg, and P | 3–4 |
| Amines | Aminobutyric acid, α-amino acids | 1 |
| Noradrenaline | 0.1–0.5 | |
| Histamine | 0.5–2 | |
| Dopamine | 0.2–1 | |
| Volatile compounds | Complex ethers | 4–8 |
Antiviral activities of bee venom and its components.
| Bee Venom or Extract | Organism | Tested Model | Outcome of the Study | References |
|---|---|---|---|---|
| Bee venom | Vesicular stomatitis virus (VSV), coxsackievirus (H3), herpes simplex virus (HSV), enterovirus-71 (EV-71), influenza A virus (PR8), and respiratory syncytial virus (RSV) | In vitro HEK293T, MDCK, HEp2, Vero cells, and HeLa | It is concluded that bee venom would be a promising antiviral agent, especially in the establishment of a broad-spectrum antiviral agent. | [ |
| Bee venom | Porcine reproductive and | In vivo | Especially nasal or rectal application of bee venom may be used in the prevention of this infection in pigs. | [ |
| Bee venom (phospholipase A2) | Dengue virus (DENV), hepatitis C virus (HCV), and Japanese encephalitis virus (JEV) | In vitro Huh7it-1 cells, MDCK, HEK293T, and Vero cells and in vivo embryonated eggs | Phospholipase A2 and its derivatives could be potent candidates for the development of broad-spectrum antiviral drugs that exert their effects by targeting viral envelope lipid bilayers derived from the ER membrane. | [ |
| Bee venom | Lumpy skin disease virus (LSDV) | In vitro Maiden-Darby bovine kidney cells (MDBK), Hep-2, and MCF7 and in vivo embryonated chicken eggs | Bee venom could serve as a good treatment for LSDV after determination of suitable therapeutic doses. | [ |
Figure 7General composition of royal jelly.
Figure 8General composition of beeswax.